4 news items
Mustang Bio Announces Closing of $4 Million Public Offering
FBIO
MBIO
2 May 24
to preclinical and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage
Mustang Bio Announces Pricing of $4 Million Public Offering
FBIO
MBIO
29 Apr 24
suppliers; our ability to attract, integrate and retain key personnel; the early stage of products under development; our need for substantial additional
Mustang Bio Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases
FBIO
MBIO
28 Mar 24
and clinical testing; our dependence on third-party suppliers; our ability to attract, integrate and retain key personnel; the early stage of products
Mustang Bio Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101 IL13Rα2-targeted CAR T-Cells in High-Grade Glioma
FBIO
MBIO
7 Mar 24
to the timing of starting and completing clinical trials; uncertainties relating to preclinical and clinical testing; our dependence on third-party suppliers; our
- Prev
- 1
- Next